Development Strategy

Robust Pipeline Clinical Development Technology Platform Collaborations

Pipeline

Robust Pipeline with global rights and lead positions

Fields	Project/Modality	Target	Indications
Nephropathy	SC0062 SM	ETA	lgA
Nephropathy	SC0062 SM	ETA	DKD
CKD Area，SC0062, a highly ETA-Selective receptor antagonist，has completed phaseⅠ trial in healthy volunteers showing favorable safety profile，no edema reported. SC0062 has the characteristics of high ETA/ETB selection ratio and has the potential make a breakthroughs in CKD ( such as IgA、DKD）.
Oncology	BC3195 ADC	CDH3	Soild tumor
BC3195 represents a groundbreaking first-in-class CDH3-directed antibody drug conjugate that is currently in phase I of clinical trial in China and U.S. This powerful molecule is expertly designed to compose a novel anti-CDH3 mAb, a cleavable linker, and a clinically validated payload with bystander killing effect.
Oncology	BC3402 mAb	TIM-3	HCC
Oncology	BC3402 mAb	TIM-3	MDS/CMML
Immune Checkpoint，BC3402 is a humanized TIM-3 monoclonal antibody, currently in PhaseⅠdose escalation. In Preclinical studies，BC3402 has shown a strong T cell activation and inhibition of Treg，and demonstrated high antitumor activity as a single agent or in combination with other agents in a variety of animal models.
Oncology	BC3448 BsAb	CD3xEGFR	Solid tumor
T-Cell Engager，BC3448 is a CD3xEGFR bispecific antibody that activates T cells to kill tumor cells with EGFR expression，and designed to have a stronger binding affinity for EGFR than that for CD3, which may help re-duce the risk of cytokine release syndrome (CRS）. In preclinical in vitro and in vivo studies, BC3448 demonstrated antitumor activities regardless of the mutation status of EGFR, KRAS or BRAF genes. BC3448 is in PhaseⅠdose escalation.
Oncology	SC0191 SM	WEE1	Solid tumor
			Solid tumor
			OC
DDR Pathway，SC0191 is the first WEE1 Kinase small molecule inhibitor IND approved by NMPA，currently in PhaseⅠdose escalation. In preclinical studies, SC0191 has shown favorable safety profile and demonstrated high antitumor activity as a single agent or in combination with other agents in a variety of animal models.
Oncology	SC0245 SM	ATR	Solid tumor
Oncology	SC0245 SM	ATR	SCLC
DDR Pathway, SC0245 is the first ATR Kinase small molecule inhibitor IND approved by NMPA，currently in PhaseⅠdose escalation. In preclinical studies, SC0245 has shown favorable safety 、tolerability and pharmacokinetic profiles，and demonstrated high antitumor activity as a single agent or in combination with other agents in a variety of animal models.
Oncology	BC3425 mAb	4-1BB	Solid tumor
Immune agonist，BC3425 is a fully human 4-1BB monoclonal antibody with different epitopes, currently in PhaseⅠdose escalation and no liver tox observed yet. In preclinical studies, BC3425 has demonstrated antitumor activity in a variety of animal models with low liver tox，is expected to have a wide treatment window.
Oncology	ADC	Undisclosed	Solid tumor

Oncology	Bs-Ab	Undisclosed	Solid tumor

Highly Differentiated

Science-Driven

Deeply understand the scientific mechanism, and improve the success rate of target selection

Clinically-Oriented

Strive to meet the unmet medical needs of the future and to foresee the trend the future clinical treatment scenarios

Long-term Commerical Value

Develop products with long-term commercial value

Focused Area

From anti-tumor to anti-tumor resistance

Chronic kidney disease(CKD)

Oncology

From anti-tumor to anti-tumor resistance